Floyd CN, Ferro A. Indications for anticoagulant and antiplatelet combined therapy. BMJ. 2017. https://doi.org/10.1136/bmj.j3782.

Article  PubMed  Google Scholar 

Barnes GD. Combining antiplatelet and anticoagulant therapy in cardiovascular disease. Hematol Am Soc Hematol Educ Program. 2020;2020:642–8.

Article  Google Scholar 

Hansen ML, Sørensen R, Clausen MT, Fog-Petersen ML, Raunsø J, Gadsbøll N, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med. 2010. https://doi.org/10.1001/archinternmed.2010.271.

Article  PubMed  Google Scholar 

Gibson CM, Mehran R, Bode C, Halperin J, Verheugt FW, Wildgoose P, et al. Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med. 2016;375:2423–34.

Article  CAS  PubMed  Google Scholar 

Lopes RD, Heizer G, Aronson R, Vora AN, Massaro T, Mehran R, et al. Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation. N Engl J Med. 2019;380:1509–24.

Article  CAS  PubMed  Google Scholar 

January CT, Wann LS, Calkins H, Chen LY, Cigarroa JE, Cleveland JC, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation. J Am Coll Cardiol. 2019;74:104–32.

Article  PubMed  Google Scholar 

Capodanno D, Huber K, Mehran R, Lip GYH, Faxon DP, Granger CB, et al. Management of antithrombotic therapy in atrial fibrillation patients undergoing PCI. J Am Coll Cardiol. 2019;74:83–99.

Article  PubMed  Google Scholar 

Dayoub EJ, Seigerman M, Tuteja S, Kobayashi T, Kolansky DM, Giri J, et al. Trends in platelet adenosine diphosphate P2Y12 receptor inhibitor use and adherence among antiplatelet-naive patients after percutaneous coronary intervention, 2008–2016. JAMA Intern Med. 2018;178:943.

Article  PubMed  PubMed Central  Google Scholar 

Colacci M, Tseng EK, Sacks CA, Fralick M. Oral anticoagulant utilization in the United States and United Kingdom. J Gen Intern Med. 2020;35:2505–7.

Article  PubMed  PubMed Central  Google Scholar 

Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, et al. Antithrombotic therapy for VTE disease. Chest. 2016;149:315–52.

Article  PubMed  Google Scholar 

Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly diagnosed atrial fibrillation. Am J Cardiol. 2017;120:1813–9.

Article  CAS  PubMed  Google Scholar 

Abraham NS, Noseworthy PA, Yao X, Sangaralingham LR, Shah ND. Gastrointestinal safety of direct oral anticoagulants: a large population-based study. Gastroenterology. 2017;152:1014-1022.e1.

Article  CAS  PubMed  Google Scholar 

Själander S, Sjögren V, Renlund H, Norrving B, Själander A. Dabigatran, rivaroxaban and apixaban vs. high TTR warfarin in atrial fibrillation. Thromb Res. 2018;167:113–8.

Article  PubMed  Google Scholar 

Mueller T, Alvarez-Madrazo S, Robertson C, Wu O, Bennie M. Comparative safety and effectiveness of direct oral anticoagulants in patients with atrial fibrillation in clinical practice in Scotland. Br J Clin Pharmacol. 2019;85:422–31.

Article  CAS  PubMed  Google Scholar 

Fralick M, Colacci M, Schneeweiss S, Huybrechts KF, Lin KJ, Gagne JJ. Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study. Ann Intern Med. 2020;172:463.

Article  PubMed  Google Scholar 

Bott-Kitslaar DM, McBane RD, Casanegra AI, Houghton DE, Froehling DA, Vlazny DT, et al. Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc. 2019;94:1242–52.

Article  CAS  PubMed  Google Scholar 

Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019;6:e20–8.

Article  PubMed  Google Scholar 

Howe Z, Naville-Cook C, Cole D. Bleeding rates of Veterans taking apixaban or rivaroxaban for atrial fibrillation or venous thromboembolism. J Thromb Thrombolysis. 2019;47:280–6.

Article  CAS  PubMed  Google Scholar 

Sindet-Pedersen C, Staerk L, Pallisgaard JL, Gerds TA, Berger JS, Torp-Pedersen C, et al. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2018;4:220–7.

Article  PubMed  Google Scholar 

Lutsey PL, Zakai NA, MacLehose RF, Norby FL, Walker RF, Roetker NS, et al. Risk of hospitalised bleeding in comparisons of oral anticoagulant options for the primary treatment of venous thromboembolism. Br J Haematol. 2019;185:903–11.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Jin MC, Sussman ES, Feng AY, Han SS, Skirboll SL, Berube C, et al. Hemorrhage risk of direct oral anticoagulants in real-world venous thromboembolism patients. Thromb Res. 2021;204:126–33.

Article  CAS  PubMed  Google Scholar 

Dawwas GK, Leonard CE, Lewis JD, Cuker A. Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data. Ann Intern Med. 2022;175:20–8.

Article  PubMed  Google Scholar 

Vinogradova Y, Coupland C, Hill T, Hippisley-Cox J. Risks and benefits of direct oral anticoagulants versus warfarin in a real world setting: cohort study in primary care. BMJ. 2018. https://doi.org/10.1136/bmj.k2505.

Article  PubMed  PubMed Central  Google Scholar 

Ingason AB, Hreinsson JP, Ágústsson AS, Lund SH, Rumba E, Pálsson DA, et al. Rivaroxaban is associated with higher rates of gastrointestinal bleeding than other direct oral anticoagulants: a nationwide propensity score-weighted study. Ann Intern Med. 2021. https://doi.org/10.7326/M21-1474.

Article  PubMed  Google Scholar 

Yoshida K, Solomon DH, Kim SC. Active-comparator design and new-user design in observational studies. Nat Rev Rheumatol. 2015;11:437–41.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Merative. Merative MarketScan Research Databases. 2022; Available from: https://www.merative.com/content/dam/merative/documents/brief/Marketscan_explainer_general.pdf.coredownload.inline.pdf?gclid=Cj0KCQiA-JacBhC0ARIsAIxybyMe3JUa8LHdxY1H_zfM6f_FfSTjFLjLvfPoY4DMBj6blDKpscX46tQaAmIyEALw_wcB&gclsrc=aw.ds

von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the reporting of observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806–8.

Article  Google Scholar 

Langan SM, Schmidt SA, Wing K, Ehrenstein V, Nicholls SG, Filion KB, et al. The reporting of studies conducted using observational routinely collected health data statement for pharmacoepidemiology (RECORD-PE). BMJ. 2018. https://doi.org/10.1136/bmj.k3532.

Article  PubMed  PubMed Central  Google Scholar 

Wang SV, Pinheiro S, Hua W, Arlett P, Uyama Y, Berlin JA, et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372: m4856.

Article  PubMed  PubMed Central  Google Scholar 

Go AS, Singer D, Cheetham TC, Toh D, Reichman M, Graham D, et al. Mini-sentinel medical product assessment a protocol for assessment of dabigatran. Sentinel Initiative. 2015. Available from: https://www.sentinelinitiative.org/sites/default/files/Drugs/Assessments/Mini-Sentinel_Protocol-for-Assessment-of-Dabigatran_0.pdf

Jun M, James MT, Manns BJ, Quinn RR, Ravani P, Tonelli M, et al. The association between kidney function and major bleeding in older adults with atrial fibrillation starting warfarin treatment: population based observational study. BMJ. 2015;350:h246–h246.

Article  PubMed  PubMed Central  Google Scholar 

Oger E, Botrel M-A, Juchault C, Bouget J. Sensitivity and specificity of an algorithm based on medico-administrative data to identify hospitalized patients with major bleeding presenting to an emergency department. BMC Med Res Methodol. 2019;19:194.

Article  PubMed  PubMed Central  Google Scholar 

Hernán MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183:758–64.

Article  PubMed  PubMed Central  Google Scholar 

Quan H, Sundararajan V, Halfon P, Fong A, Burnand B, Luthi J-C, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43:1130–9.

Article  PubMed  Google Scholar 

Fang MC, Fan D, Sung SH, Witt DM, Schmelzer JR, Steinhubl SR, et al. Validity of using inpatient and outpatient administrative codes to identify acute venous thromboembolism: the CVRN VTE study. Med Care. 2017;55:e137–43.

Article  PubMed  PubMed Central  Google Scholar 

Li A, Li MK, Crowther M, Vazquez SR. Drug-drug interactions with direct oral anticoagulants associated with adverse events in the real world: a systematic review. Thromb Res. 2020;194:240–5.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Nakasian SS, Rassen JA, Franklin JM. Effects of expanding the look-back period to all available data in the assessment of covariates. Pharmacoepidemiol Drug Saf. 2017;26:890–9.

Article  PubMed  Google Scholar 

Austin PC. An introduction to propensity score methods for reducing the effects of confounding in observational studies. Multivariate Behav Res. 2011;46:399–424.

Article